# Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study)

> **NCT07381400** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Xinhua Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 128 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** mFOLFOX6
- **DRUG:** Serplulimab

## Key facts

- **NCT ID:** NCT07381400
- **Lead sponsor:** Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2028-02-01
- **Final completion:** 2031-12-31
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07381400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07381400, "Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study)". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT07381400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*